REG - BSF Enterprise PLC - Result of Annual General Meeting

BSF EnterpriseAnnouncement

20/03/2024 13:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240320:nRST6424Ha&default-theme=true

RNS Number : 6424H  BSF Enterprise PLC  20 March 2024

20 March 2024

BSF Enterprise PLC

("BSF" or the "Company")

 

Result of Annual General Meeting

 

BSF Enterprise (LSE: BSFA), (OTCQB: BSFAF), the Main Market listed biotech
company and owner of pioneering UK-based tissue engineering company 3D
Bio-Tissues Ltd (3DBT) and corneal tissue replacement company Kerato Ltd, is
pleased to announce that at the Company's Annual General Meeting held earlier
today, all resolutions proposed were duly passed by shareholders by way of a
poll, the results of which were as follows:

 

 Resolution      Poll Results
         For     Against     Withheld  Discretionary  Total
 1       Shares  52,426,227  -         -              -      52,426,227
         %       100.00%     -         -              -      100%
 2       Shares  52,421,227  5,000     -              -      52,426,227
         %       99.99%      0.01%     -              -      100%
 3       Shares  52,421,227  5,000     -              -      52,426,227
         %       99.99%      0.01%     -              -      100%
 4       Shares  52,426,227  -         -              -      52,426,227
         %       100.00%     -                        -      100%
 5       Shares  46,646,377  -         5,779,850      -      52,426,227
         %       88.98%      -         11.02%         -      100%
 6       Shares  52,426,227  -         -              -      52,426,227
         %       100.00%     -         -              -      100%
 7       Shares  52,402,826  23,401    -              -      52,426,227
         %       99.96%      0.04%     -              -      100%
 8       Shares  52,421,227  -         5,000          -      52,426,227
         %       99.99%      -         0.01%                 100%
 9       Shares  52,397,826  23,401    5,000          -      52,426,227
         %       99.95%      0.04%     0.01%          -      100%

 

 

About BSF Enterprise PLC:

BSF Enterprise PLC (BSF) is focused on unlocking the next generation of
biotechnological solutions - using cellbased tissue engineering to help
generate cultured meat, lab-grown leather, as well as human corneas, collagen
growth and skin substitutes, as part of a radical transformation to deliver
sustainable solutions across a variety of sectors.

 

It owns 100% of 3D Bio-Tissues (3DBT), a tissue engineering with
patent-protected IP that is already producing human corneas for testing to
help restore vision to millions of people. Building on this success, it aims
to produce the UK's first high quality leather from its laboratory in
Newcastle, transforming the leather industry towards an ethical and
sustainable practice.

 

BSF aims to deliver growth to shareholders through the continued
commercialisation of 3DBT's IP, which has multiple applications, as well as
through M&A. It aims to develop a suite of technologies that underpins the
development of tissue templating for corneas, meat and leather, and license
out the IP to manufacturers, wholesalers and distributors to help manufacture
the products at scale.

 

For further enquiries, please visit www.bsfenterprise.com or contact:

 

 BSF Enterprise PLC                      Via SEC Newgate below
 Geoff Baker - Executive Director

 Che Connon - CEO & Director

 Shard Capital (Broker)
 Damon Heath                             0207 186 9000

Isabella Pierre

                                         0207 186 9927

 SEC Newgate (Financial Communications)
 Bob Huxford                             020 3757 6882
 Elisabeth Cowell                        BSF@secnewgate.co.uk

 

 

ISIN of the Ordinary Shares is GB00BHNBDQ51

SEDOL Code is BHNBDQ5.

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  RAGURVURSVUOUAR